Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Goldman, Templeton, Fidelity Anchor NSE IPO Despite Valuation Concerns as India’s Exchange Downsizes Offer

by Team Lumida
September 15, 2026
in Equities
Reading Time: 4 mins read
A A
0
Goldman Sachs Urges Investors to Cut Risk: Is a Selloff Looming?

Source: LeapRate

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Goldman Sachs Asset Management, Franklin Templeton, and Fidelity International are anchoring the National Stock Exchange of India’s long-awaited IPO, joined by sovereign wealth funds including Norges Bank, Abu Dhabi Investment Authority, and GIC. The anchor book will reach approximately 68 billion rupees, with NSE aiming to raise 226 billion rupees ($2.4 billion) at a price band of 1,700-1,785 rupees per share, down from an initially marketed range of 2,000-2,100 rupees.
  • Several prominent asset managers—Capital Group, BlackRock, Aberdeen, Fidelity Investments (FMR), and T. Rowe Price—are skipping the offering amid valuation concerns. The mixed response reflects investor wariness over regulatory risks, slowing growth, and the crash in options trading—historically NSE’s largest earnings driver. Indian authorities are clamping down on speculative derivatives to cool what was the world’s largest options boom.
  • NSE’s price-band reduction signals a rebalancing between growth prospects and investor skepticism over regulatory headwinds. The world’s largest derivatives exchange by volume remains profitable and dominant in India, but the regulatory pivot toward restricting options activity undermines the thesis that drove historical valuation premiums. Institutional investors are pricing in lower medium-term earnings growth as derivatives volumes face structural pressure.
  • The IPO opens for anchor investment September 16 and retail orders from September 17-21, with a potential listing on September 24. The mixed anchor book—heavyweight acceptance from sovereign wealth funds but skepticism from major asset managers—signals that global institutional capital values NSE’s market position but discounts future growth assumptions given regulatory tightening and valuation risk.

What Happened?

The National Stock Exchange of India attracted commitments from Goldman Sachs Asset Management, Franklin Templeton, Fidelity International, and major sovereign wealth funds including Norges Bank Investment Management, Abu Dhabi Investment Authority, and GIC to anchor its IPO. The anchor book reached approximately 68 billion rupees. However, several prominent global asset managers—Capital Group, BlackRock, Aberdeen, FMR, and T. Rowe Price—opted to sit out the offering, citing valuation concerns and regulatory risks. NSE reduced its price band to 1,700-1,785 rupees per share from an initially marketed 2,000-2,100 rupees, aiming to raise 226 billion rupees ($2.4 billion). Anchor orders close September 16, with retail orders through September 21 and potential listing on September 24.

Why It Matters?

For equity investors and allocators focused on emerging market infrastructure, the bifurcated response to NSE’s IPO reveals a valuation inflection point. Sovereign wealth funds—with long time horizons and less sensitivity to near-term regulation—are buying. Tactical asset managers worried about earnings revisions are abstaining. This divergence signals that NSE’s multiyear growth story, built on derivatives trading volume and market depth, is being repriced lower as Indian regulators throttle options activity to reduce retail speculation and systemic risk. For investors in global exchange operators (CME, Eurex, LSE), NSE’s valuation reset provides a comparable. The absence of major U.S. asset managers (BlackRock, Capital Group, FMR) suggests they believe either valuation is still too high relative to regulatory risks, or that earnings multiple compression outweighs the appeal of a dominant market position. The options trading crackdown also creates a cautionary tale: regulators can move quickly to restrict profitable segments, eroding growth narratives that justified premium valuations.

What’s Next?

Monitor the final anchor book size when it closes September 16—if commitments shrink or top managers withdraw, it signals deeper skepticism. Track the retail demand during September 17-21; weak retail interest would undermine the IPO’s credibility despite anchor support. Watch NSE’s proposed listing price within the band; the lower end would suggest price discovery favored skeptics, while the upper end would validate sovereign wealth fund conviction. Post-listing, focus on quarterly options trading volumes and any further regulatory announcements from India’s Securities and Exchange Board; continued crackdowns would validate bears, while stabilization would support bulls. Finally, compare NSE’s listed valuation multiples to CME and other global exchanges—if NSE trades at a significant discount despite dominance, it will signal sustained earnings growth concerns or geopolitical premium erosion.

Affected Tickers: GS, BLK, TROW, CME, ICE

Source: Bloomberg

Previous Post

Gold Slides Below $4,270 as Middle East Oil Disruptions Push Fed Rate-Hike Expectations to 95%

Next Post

Apple’s 16-Product Roadmap Through Mid-2027 Spotlights Siri AI Overhaul and Biggest Push Into Smart Home

Recommended For You

Prudential Moves $5 Billion to Prismic, Where More Than $22 Billion of Roughly $25 Billion in Assets Already Relates to Prudential

by Team Lumida
5 hours ago
Prudential Moves $5 Billion to Prismic, Where More Than $22 Billion of Roughly $25 Billion in Assets Already Relates to Prudential

The reinsurer has external investors including Warburg Pincus, but its book is overwhelmingly one client's risk.

Read more

Citi Cuts Its Analyst Programme to Two Years as Banks Compete on Tenure Because They Cannot Compete on Carry

by Team Lumida
6 hours ago
Citi Cuts Its Analyst Programme to Two Years as Banks Compete on Tenure Because They Cannot Compete on Carry

Shortening promotion timelines moves an entire cohort onto associate pay a year earlier, permanently, to defend against a rival pay structure.

Read more

Singapore Exchange Craters on Valuation Reckoning — $4.2B Wiped Out as Analysts Unleash Downgrades on 26x Forward Multiple Disconnect

by Team Lumida
9 hours ago
Singapore Exchange Craters on Valuation Reckoning — $4.2B Wiped Out as Analysts Unleash Downgrades on 26x Forward Multiple Disconnect

SGX shares down 19% since Aug 26 peak, lost $4.2B market value. Trading 26x forward earnings (vs 10-year avg 22x, STI 16x). Citi downgrade: sell, 90-day negative catalyst...

Read more

Bank Stocks Spooked by 2023 Flashbacks — KBW Index Crashes Despite Better Balance Sheets as Deposit Attrition Fears and AI Deposit Flight Haunt Lenders

by Team Lumida
9 hours ago
Bank Stocks Spooked by 2023 Flashbacks — KBW Index Crashes Despite Better Balance Sheets as Deposit Attrition Fears and AI Deposit Flight Haunt Lenders

KBW Nasdaq Bank index down 9% past month (vs S&P 500 flat). Unrealized securities losses $330B (14% of Tier 1 capital, down from 33% in Q3 2022). Bond...

Read more

Industrial Software Consolidation Accelerates — Schneider Electric Swallows PTC for $22.6B as AI Reshapes Factory Automation Landscape

by Team Lumida
10 hours ago
Industrial Software Consolidation Accelerates — Schneider Electric Swallows PTC for $22.6B as AI Reshapes Factory Automation Landscape

Schneider Electric (France) agreed all-cash acquisition PTC (US industrial software) for $22.6B. Offer: $205/share (42% premium to last close). PTC board recommended shareholder approval. Deal creates largest industrial-software...

Read more

Physical AI Goes Mainstream — German Robotics Startup RobCo Hits $1B Valuation as Self-Learning Robots Answer Manufacturing’s Labor Crisis

by Team Lumida
10 hours ago
Physical AI Goes Mainstream — German Robotics Startup RobCo Hits $1B Valuation as Self-Learning Robots Answer Manufacturing’s Labor Crisis

RobCo German robotics startup valued at $1B+ (double $500M January valuation) in $40M share sale. Flagship: Alfie two-armed self-learning robot mimic factory workers. Investors: Cherry Ventures, European Tech...

Read more

Tesla Delivers 486,532 Vehicles, Beating Estimates, Helped by Chinese-Built Cars Entering Canada Under a 6.1% Tariff Quota

by Team Lumida
3 days ago
Tesla Delivers 486,532 Vehicles, Beating Estimates, Helped by Chinese-Built Cars Entering Canada Under a 6.1% Tariff Quota

An American company is supplying the Canadian market from Chinese factories under a Carney-Xi agreement, bypassing the US-Canada trade dispute.

Read more

SEC Censures JPMorgan With No Fine After a Disqualified Trader Handled 800 Swap Transactions Over Two Years

by Team Lumida
3 days ago
SEC Censures JPMorgan With No Fine After a Disqualified Trader Handled 800 Swap Transactions Over Two Years

The regulator cited self-reporting and remediation in imposing no penalty, a concrete data point on what voluntary disclosure is worth.

Read more

Novartis Inks Chinese mRNA-Therapy Deal; Abogen Biosciences $7.8B; ABO2203 Autoimmune T-Cell Engager; $575M Upfront; White Blood Cell Depletion; Novo Nordisk Jiangsu Hengrui $2.6B Obesity Pill; AstraZeneca Summit $2B Cancer; Chimagen GSK Blood-Cancer; Big Pharma China Drug Licensing Trend

by Team Lumida
3 days ago
Novartis Inks Chinese mRNA-Therapy Deal; Abogen Biosciences $7.8B; ABO2203 Autoimmune T-Cell Engager; $575M Upfront; White Blood Cell Depletion; Novo Nordisk Jiangsu Hengrui $2.6B Obesity Pill; AstraZeneca Summit $2B Cancer; Chimagen GSK Blood-Cancer; Big Pharma China Drug Licensing Trend

Novartis AG licensing mRNA-based autoimmune therapy from China's Abogen Biosciences. Deal worth $7.8B (up to $7.2B additional milestones). $575M upfront for mRNA-encoded T-cell engager (ABO2203). Drug resets immune...

Read more

IG Group Holdings Stock Plunges 27%; Q3 Revenue Surprise Slump; £240M Q3 Sales -14% YoY; May Guidance Cut 10-15% to Mid-Single Digit; Over-the-Counter Revenue -18%; Customer Income +8%; Underdog Acquisition $1.3B July; Oct 22 Strategy Update

by Team Lumida
3 days ago
IG Group Holdings Stock Plunges 27%; Q3 Revenue Surprise Slump; £240M Q3 Sales -14% YoY; May Guidance Cut 10-15% to Mid-Single Digit; Over-the-Counter Revenue -18%; Customer Income +8%; Underdog Acquisition $1.3B July; Oct 22 Strategy Update

IG Group Holdings Plc shares plummeted 27% (steepest intraday decline since Dec 2016). Q3 revenue expected £240M (~$317M)—14% drop vs prior year. Company cut 2026 guidance: expected mid-single...

Read more
Next Post
Apple’s 16-Product Roadmap Through Mid-2027 Spotlights Siri AI Overhaul and Biggest Push Into Smart Home

Apple's 16-Product Roadmap Through Mid-2027 Spotlights Siri AI Overhaul and Biggest Push Into Smart Home

Bank of England Eyes End to Long-Dated Bond Sales as 30-Year Gilts Approach 6%, Shifting Quantitative Tightening Strategy

Bank of England Eyes End to Long-Dated Bond Sales as 30-Year Gilts Approach 6%, Shifting Quantitative Tightening Strategy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

gray airplane on parking

U.S. to Reduce Flight Traffic by 10% at 40 Airports Because of Shutdown

November 6, 2025
aerial view of city buildings during daytime

US–Iran War Escalates After Khamenei Killed, Oil Surges and Markets Turn Risk-Off

March 2, 2026
blue and yellow striped country flag

Zelenskiy Loses Key Adviser Amid Corruption Probe as US Pressure Intensifies on Ukraine Peace Deal

November 29, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018